Elanco Secures USDA Nod for First 0.5mL Lyme-Leptospirosis Dog Vaccine

Event summary

  • Elanco's TruCan Ultra Lyme-L4 received USDA approval on June 15, 2026, becoming the first 0.5mL combination vaccine for Lyme disease and leptospirosis in dogs.
  • The vaccine uses Elanco's proprietary PureFil Technology to reduce adverse reactions while maintaining 92.2% efficacy in endemic areas.
  • Over 40% of at-risk dogs in endemic states lack current Lyme vaccination despite receiving core vaccines.
  • Product shipping begins within 30 days, following recent USDA approvals of two other TruCan Ultra vaccines.

The big picture

This approval strengthens Elanco's position in the growing pet health market, particularly as leptospirosis vaccination becomes a core recommendation. The company is strategically expanding its TruCan Ultra portfolio with low-volume, highly purified vaccines that address critical protection gaps. With Lyme disease spreading to new geographies and significant under-vaccination in endemic areas, this product could drive meaningful revenue growth.

What we're watching

Market Adoption
How quickly veterinarians and pet owners will transition to this combination vaccine format.
Competitive Response
Whether competitors will accelerate development of similar low-volume combination vaccines.
Regulatory Expansion
The pace at which Elanco can secure approvals for similar products in international markets.